OLMA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.532

+4.25%

-0.558

+55%

-0.588

+15.29%

Estimates Revision

The market is revising No Change the revenue expectations for Olema Pharmaceuticals, Inc. (OLMA) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 153.65%.

Revenue Estimates for FY2026

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+3%

In Past 3 Month

Stock Price

Go Up

+153.65%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast OLMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OLMA is 36.83 USD with a low forecast of 20.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

20.00

Averages

36.83

High

55.00

Current: 0.000

Low

20.00

Averages

36.83

High

55.00

UBS

Buy

initiated

$45

2026-01-07

New

Reason

UBS

Price Target

$45

2026-01-07

New

initiated

Buy

Reason

UBS initiated coverage of Olema Oncology (OLMA) with a Buy rating and $45 price target as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.

Piper Sandler

Overweight

initiated

$40

2026-01-07

New

Reason

Piper Sandler

Price Target

$40

2026-01-07

New

initiated

Overweight

Reason

Piper Sandler initiated coverage of Olema Oncology with an Overweight rating and $40 price target. The firm believes the company's palazestrant can become the next "backbone" endocrine therapy in the large ER+/HER2- breast cancer market.

Citi

Yigal Nochomovitz

Buy

maintain

$60

2026-01-06

New

Reason

Citi

Yigal Nochomovitz

Price Target

$60

2026-01-06

New

maintain

Buy

Reason

Citi analyst Yigal Nochomovitz keeps a Buy rating on Olema Oncology with a $60 price target while adding an "upside 90-day catalyst watch" on the shares. The firm sees opportunities in SMID-cap biotech heading into 2026 for commercial or near-commercial stage companies.

Citi

Buy

maintain

$21 -> $60

2025-12-12

Reason

Citi

Price Target

$21 -> $60

2025-12-12

maintain

Buy

Reason

Citi raised the firm's price target on Olema Oncology (OLMA) to $60 from $21 and keeps a Buy rating on the shares. Citi also added an "upside 90-day catalyst watch" on Olema. The firm says Roche's (RHHBY) positive Phase 3 lidERA trial data shows the "practice changing" potential of selective estrogen receptor degraders for adjuvant treatment of breast cancer. The data bode well for Olema, the analyst tells investors in a research note.

Oppenheimer

Outperform

maintain

$45 -> $48

2025-12-11

Reason

Oppenheimer

Price Target

$45 -> $48

2025-12-11

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Olema Oncology (OLMA) to $48 from $45 and keeps an Outperform rating on the shares. The firm says Roche's (RHHBY) lidERA results marked the first time an oral selective estrogen receptor degrader beat an aromatase inhibitor "fair and square." Oppenheimer says only Olema's palazestrant can match Roche's giredestrant. "As the best oral SERD out there (in our view), lidERA considerably boosts palazestrant's optionality," the analyst tells investors in a research note.

Goldman Sachs

Buy

upgrade

$26 -> $38

2025-12-11

Reason

Goldman Sachs

Price Target

$26 -> $38

2025-12-11

upgrade

Buy

Reason

Goldman Sachs raised the firm's price target on Olema Oncology (OLMA) to $38 from $26 and keeps a Buy rating on the shares. Roche's (RHHBY) detailed Phase 3 lidERA results for giredestrant at the San Antonio Breast Cancer Symposium showed encouraging efficacy with a safety/tolerability profile that supports SERD monotherapy as a viable adjuvant option for ER+/HER2- breast cancer, offering positive read-through for Olema's palazestrant and its potential to expand into the large adjuvant market, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Olema Pharmaceuticals Inc (OLMA.O) is -11.64, compared to its 5-year average forward P/E of -6.26. For a more detailed relative valuation and DCF analysis to assess Olema Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.26

Current PE

-11.64

Overvalued PE

-0.22

Undervalued PE

-12.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.10

Current EV/EBITDA

-8.30

Overvalued EV/EBITDA

2.22

Undervalued EV/EBITDA

-8.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

42.49

Current PS

1193.09

Overvalued PS

253.39

Undervalued PS

-168.41

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 8218.16% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 8218.16% over the last month.

Sold

Bought

OLMA News & Events

Events Timeline

No data

News

4.0

01-07Yahoo Finance

Olema Pharmaceuticals (OLMA) Receives Buy Rating with $45 Price Target

1.0

01-05Globenewswire

Olema Pharmaceuticals to Present at 44th J.P. Morgan Healthcare Conference on January 13, 2025

2.0

2025-12-15Benzinga

Kyverna Therapeutics, Immunome, Almonty Industries, and Other Major Stocks Rise on Monday

People Also Watch

Frequently Asked Questions

What is Olema Pharmaceuticals Inc (OLMA) stock price today?

The current price of OLMA is 27.09 USD — it has increased 5.94 % in the last trading day.

What is Olema Pharmaceuticals Inc (OLMA)'s business?

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.

What is the price predicton of OLMA Stock?

What is Olema Pharmaceuticals Inc (OLMA)'s revenue for the last quarter?

Olema Pharmaceuticals Inc revenue for the last quarter amounts to -45.88M USD, increased 21.95 % YoY.

What is Olema Pharmaceuticals Inc (OLMA)'s earnings per share (EPS) for the last quarter?

Olema Pharmaceuticals Inc. EPS for the last quarter amounts to -34527000.00 USD, increased 27.80 % YoY.

What changes have occurred in the market's expectations for Olema Pharmaceuticals Inc (OLMA)'s fundamentals?

How many employees does Olema Pharmaceuticals Inc (OLMA). have?

Olema Pharmaceuticals Inc (OLMA) has 96 emplpoyees as of January 09 2026.

What is Olema Pharmaceuticals Inc (OLMA) market cap?

Today OLMA has the market capitalization of 2.01B USD.